# US 2012/0251525 A1 · Method of utilizing azelaic acid esters to modulate communications mediated by biological molecules

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251525 A1
- Document ID: US20120251525A1
- Status: Published application
- Kind: A1
- Application number: 13/449,804
- Filed: 2012-04-18
- Published: 2012-10-04
- Earliest claimed: 2009-06-30
- Inventors: Robert T. Streeper; Elzbieta Izbicka
- Web page: https://patentgrep.com/patent/US20120251525A1

## CPC

- A61K 31/23: of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 17/10: Anti-acne agents
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The treatment of disease in organisms using Macromolecular interaction modulators and Membrane active immunomodulators, particularly selected azelaic acid esters, individually and in combinations, to modulate communications between biological molecules.

## Claims

### Claim 1

A method of treating medical or cosmetic conditions comprising administering topically, nasally, orally, intravenously, by inhalation, by insufflation, intrathecally, anally, rectally, vaginally, intra-arterially, transdermally, subcutaneously, intramuscularly or parenterally, a modulator compound to modulate interactions between at least 2 biological molecules in an organism.

### Claim 2 (depends on 1)

The method of claim 1, wherein the modulator compound is at least one macromolecular interaction modulator.

### Claim 3 (depends on 1)

The method of claim 1, wherein the modulator compound is at least one membrane active immunomodulator.

### Claim 4 (depends on 1)

The method of claim 1, wherein the modulator compound is at least one azelaic acid ester compound.

### Claim 5 (depends on 4)

The method of claim 4, wherein said azelaic acid ester compound is of the formula I:
R2OOC—(CH2)n—COOR1
wherein:
a) R1 is selected from a group consisting of hydrogen, alkyl groups of up to about 18 carbon atoms, aryl groups of up to about 18 carbon atoms, alkylene group of up to about 18 carbon atoms and an arylene group of up to about 18 carbon atoms, wherein the alkyl, aryl and alkylene groups may be substituted or unsubstituted, branched or straight chains and R1 may contain heteroatoms and may be straight chained or branched;
b) R2 is selected from a group consisting of hydrogen, alkyl groups of up to about 18 carbon atoms, aryl groups of up to about 18 carbon atoms, alkylene group of up to about 18 carbon atoms and an arylene group of up to about 18 carbon atoms, wherein the alkyl, aryl and alkylene groups may be substituted or unsubstituted, branched or straight chains and R2 may contain heteroatoms and may be straight chained or branched; and
c) n, (i.e. the number of carbon atoms in the alkyl chain of the acid), is between 1 and 18 carbon atoms.

### Claim 6 (depends on 5)

The method of claim 5 wherein the value of n is preferably an odd number.

### Claim 7 (depends on 6)

The method of claim 6 wherein the value of n is 7 carbon atoms.

### Claim 8 (depends on 5)

The method of claim 5 wherein R1 is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, 2-pentyl, 3-pentyl, hexyl, 2-hexyl, 3-hexyl, heptyl, 2-heptyl, 3-heptyl, 4-heptyl, octyl, nonyl, decyl, undecyl, dodecyl, trisdecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl and octadecyl and R2 is hydrogen.

### Claim 9 (depends on 5)

The method of claim 5 wherein R1 and R2 are selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, 2-pentyl, 3-pentyl, hexyl, 2-hexyl, 3-hexyl, heptyl, 2-heptyl, 3-heptyl, 4-heptyl, octyl, nonyl, decyl, undecyl, dodecyl, trisdecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl and octadecyl where R1 and R2 are not necessarily the same.

### Claim 10 (depends on 4)

The method of claim 4, wherein the intravenous or subcutaneous administration of the at least one azelaic acid ester compound is a combination of the azelaic acid ester and one or more amphiphilic surfactant molecules.

### Claim 11 (depends on 10)

The method of claim 10, wherein the surfactant molecule is Polysorbate 80, with 0.5% by weight of at least one azelaic acid ester is added to a solution of 0.1% by weight Polysorbate 80 USP in sterile water for injection USP.

### Claim 12 (depends on 4)

The method of claim 4, wherein the intravenous administration of at least one azelaic acid ester compound is a combination of at least one azelaic acid ester and one or more amphiphilic carrier molecules.

### Claim 13 (depends on 12)

The method of claim 12, wherein the carrier molecule is human serum albumin, mixed with up to 25% by weight of at least azelaic acid ester added to a solution of 5% by weight human serum albumin in pH 7.4 phosphate buffered saline for injection USP, thoroughly mixed to ensure solubilization.

### Claim 14 (depends on 4)

The method of claim 4, wherein the long-term intravenous administration or intraperitoneal administration of at least one azelaic acid ester compound is the combination of at least azelaic acid ester with one or more amphiphilic carrier molecules

### Claim 15 (depends on 14)

The method of claim 14, wherein the carrier molecule is hydroxypropyl-beta-cyclodextrin, where up to 1% by weight of at least one azelaic acid ester is added to a solution of 0.5% by weight hydroxypropyl-beta-cyclodextrin in pH 7.4 phosphate buffered saline for injection USP, thoroughly mixed to ensure solubilization.

### Claim 16 (depends on 4)

The method of claim 4, wherein the intrathecal or subcutaneous or parenteral administration of at least one azelaic acid compound is the combination of at least one azelaic acid ester and one or more amphiphilic carrier molecules.

### Claim 17 (depends on 16)

The method of claim 16, wherein the carrier molecule is polyethylene glycol having an average molecular weight of 3400 Daltons (PEG3400), whereby 1% by weight of at least azelaic acid ester is added to a solution of 2.5% by weight PEG3400 in normal saline for injection USP, thoroughly mixed to ensure solubilization.

### Claim 18 (depends on 4)

The method of claim 4, wherein the subcutaneous administration of at least one azelaic acid ester compound to form a depot of at least one localized azelaic acid ester that is slowly released into the body by combining the at least one azelaic acid ester at a concentration of 1 to 10% by weight with a carrier comprised of sterile sesame oil with 2% w/w oleic acid USP, thoroughly mixed to ensure solubilization.

### Claim 19 (depends on 4)

The method of claim 4, wherein the topical administration of at least one azelaic acid ester at a concentration of 1 to 10% by weight with a carrier comprised of 5% by weight Dow 245 fluid, 5% by weight Dow 5225C thickener, 5% by weight Dow 2051 formulation aid, 10% by weight Azelaic Acid Ester(s) with the balance water with or without preservatives, pH adjusting agents, perfumes or colorants as desired, thoroughly mixed to ensure solubilization.

### Claim 20 (depends on 4)

The method of claim 4, wherein the topical administration of as least one azelaic acid ester at a concentration of 1 to 10% by weight with a carrier comprised of 0.5% by weight Lubrizol Carbopol Ultrez 10, 0.5% by weight Carbopol 1382 thickener, 5% by weight of at least one azelaic acid ester, with the balance water with or without preservatives, pH adjusting agents, perfumes or colorant, combined to form a polymer caused to gel by the addition of dilute sodium hydroxide solution raising the pH of the solution to between 5.5 and 7.5 as desired, thoroughly mixed to ensure solubilization.

### Claim 21 (depends on 4)

The method of claim 4, wherein the compound modulates interactions between at least 2 biological molecules in an organism with the result of inhibiting signal molecules from binding to and activating their receptors.

### Claim 22 (depends on 4)

The method of claim 4, wherein the compound modulates interactions between at least 2 biological molecules in an organism reducing the ability of signaling molecule receptors to perform their biological functions.

### Claim 23 (depends on 4)

The method of claim 4, wherein the compound modulates interactions between at least 2 biological molecules in an organism by modifying the ability of multimeric transmembrane receptors to non-covalently associate together to form active receptors.

### Claim 24 (depends on 4)

The method of claim 4, wherein the compound modulates interactions between at least 2 biological molecules in an organism by altering or reducing membrane fluidity.

### Claim 25 (depends on 4)

The method of claim 4, wherein the compound modulates interactions between at least 2 biological molecules in an organism by preventing the formation of functional receptors within lipid rafts.

### Claim 26 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modifying the interactions in solution.

### Claim 27 (depends on 26)

The method of claim 26, wherein the modified interactions are protein-protein.

### Claim 28 (depends on 26)

The method of claim 26, wherein the modified interactions are protein-small molecule.

### Claim 29 (depends on 26)

The method of claim 26, wherein the modified interactions are protein-macromolecule.

### Claim 30 (depends on 26)

The method of claim 26, wherein the modified interactions are receptor-ligand.

### Claim 31 (depends on 26)

The method of claim 26, wherein the modified interactions are toxin-protein.

### Claim 32 (depends on 26)

The method of claim 26, wherein the medium is a solution.

### Claim 33 (depends on 26)

The method of claim 26, wherein the medium is a vesicle.

### Claim 34 (depends on 26)

The method of claim 26, wherein the medium is an organelle.

### Claim 35 (depends on 26)

The method of claim 26, wherein the medium is either in, on, through or across a membrane.

### Claim 36 (depends on 26)

The method of claim 26, wherein the medium is either naturally occurring or man-made.

### Claim 37 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of receptor mediated signal transduction.

### Claim 38 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the activity of endogenous receptors associated with membrane micro-domains.

### Claim 39 (depends on 38)

The method of claim 38, wherein the membrane micro-domains are lipid rafts.

### Claim 40 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the activity or association of exogenous molecular species with one or more endogenous molecular species.

### Claim 41 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the activity or association of exogenous molecular species with one or more endogenous species associated with membrane micro-domains such as lipid rafts.

### Claim 42 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of trans-membrane signal transduction.

### Claim 43 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of intercellular signal transduction.

### Claim 44 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of intracellular signal transduction.

### Claim 45 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of immune signaling.

### Claim 46 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of exocrine signaling.

### Claim 47 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of apocrine signaling.

### Claim 48 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of holocrine signaling.

### Claim 49 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of merocrine signaling.

### Claim 50 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of endocrine signaling.

### Claim 51 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of paracrine signaling.

### Claim 52 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of autocrine signaling.

### Claim 53 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of juxtacrine signaling.

### Claim 54 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of cytokine production, release or action.

### Claim 55 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of adipokine production release or action.

### Claim 56 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of growth factor production release or action.

### Claim 57 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of chemokine production release or action.

### Claim 58 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of Toll like receptor activity, ligand binding or signaling.

### Claim 59 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of NOD receptor activity or signaling.

### Claim 60 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of dectin receptor activity of signaling.

### Claim 61 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of G protein and G-protein coupled receptor activity or signaling.

### Claim 62 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of Notch signaling.

### Claim 63 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of ion channel and ion receptor activity or signaling such as calcium channels and receptors functional in biological signal transduction .

### Claim 64 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of lipid receptor signaling.

### Claim 65 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of endocytosis.

### Claim 66 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of clathrin mediated endocytosis.

### Claim 67 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of caveolae formation and function.

### Claim 68 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of macropinocytosis.

### Claim 69 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of phagocytosis.

### Claim 70 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of exocytosis.

### Claim 71 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of emperopolesis.

### Claim 72 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of vesicle trafficking

### Claim 73 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of vesicle tethering.

### Claim 74 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of vesicle docking

### Claim 75 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of modulation of vesicle priming.

### Claim 76 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of vesicle fusion.

### Claim 77 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the activity of SNARE proteins.

### Claim 78 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of neural activity.

### Claim 79 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of neurotransmitter receptor activity.

### Claim 80 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of endosomal acidification.

### Claim 81 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of membrane fusion.

### Claim 82 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of inter-bilayer membrane fusion.

### Claim 83 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of intercellular adhesion.

### Claim 84 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of membrane polarity.

### Claim 85 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the activity of flippases.

### Claim 86 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the activity of scramblases.

### Claim 87 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the interactions of the plasma membrane and the cytoskeleton.

### Claim 88 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the activity or function of caveolae.

### Claim 89 (depends on 1)

The method of claim 1, wherein the compound modulates interactions by modification of the activity or function of the glycocalyx.

### Claim 90 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the activity or function of integral membrane proteins.

### Claim 91 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the activity or function of lipid anchored proteins.

### Claim 92 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the activity or function of peripheral membrane proteins.

### Claim 93 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of membrane fluidity.

### Claim 94 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of lipid raft structure, physicochemical properties and or function.

### Claim 95 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the activity or proteins associated with the membrane.

### Claim 96 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the activity of proteins associated with lipid rafts.

### Claim 97 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the influence of cholesterol on biological membranes.

### Claim 98 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the influence of sphingomyelin on biological membranes.

### Claim 99 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the influence of sphingolipids on biological membranes.

### Claim 100 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the activity of Fc-epsilon receptors.

### Claim 101 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the activity of T cell antigen receptors.

### Claim 102 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the activity of B cell antigen receptors.

### Claim 103 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the activity of polypeptide toxins.

### Claim 104 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the activity of toxin receptors.

### Claim 105 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of quaternary protein structure and interactions.

### Claim 106 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of quaternary protein structure and/or quaternary interactions of integral membrane proteins.

### Claim 107 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of quaternary protein structure and/or quaternary interactions of peripheral membrane proteins.

### Claim 108 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the quaternary protein structure and/or quaternary interactions of trans-membrane proteins.

### Claim 109 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of tertiary protein structure of integral membrane proteins.

### Claim 110 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of tertiary protein structure of peripheral membrane proteins.

### Claim 111 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the tertiary protein structure of trans-membrane proteins.

### Claim 112 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of secondary protein structure of integral membrane proteins.

### Claim 113 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of secondary protein structure of peripheral membrane proteins.

### Claim 114 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the secondary protein structure of trans-membrane proteins.

### Claim 115 (depends on 4)

The method of claim 4, wherein the compound modulates interactions of biological molecules involved in cell to cell adhesion.

### Claim 116 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the activity, function or structure of proteins having beta-barrel or beta-pleated sheet structural motifs.

### Claim 117 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the activity, function or structure of proteins having alpha-helix structural motifs.

### Claim 118 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the activity function or structure of uniporters.

### Claim 119 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the activity function or structure or symporters.

### Claim 120 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the activity function or structure or antiporters.

### Claim 121 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the activity of voltage gated ion channels.

### Claim 122 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the activity of large conductance mechanosensitive channels.

### Claim 123 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the activity of small conductance mechanosensitive channels.

### Claim 124 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the activity of CorA metal ion transporters.

### Claim 125 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the activity of aquaporins.

### Claim 126 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the activity of chloride channels.

### Claim 127 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the activity of outer membrane auxiliary proteins.

### Claim 128 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the activity of cytochrome P450 oxidases.

### Claim 129 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the activity of OmpA like transmembrane proteins.

### Claim 130 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the activity of virulence related outer membrane protein family proteins.

### Claim 131 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the activity of bacterial porins.

### Claim 132 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the activity of complement proteins.

### Claim 133 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the activity of mitochondrial carrier proteins.

### Claim 134 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the activity of ABC transporters.

### Claim 135 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the activity of multidrug resistance transporters.

### Claim 136 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by modification of the structure, function or activity of pathogen associated molecular pattern receptors.

### Claim 137 (depends on 4)

The method of claim 4, wherein the compound modulates the structure, function or activity of ligand gated ion channels.

### Claim 138 (depends on 4)

The method of claim 4 wherein the compound modulates the structure, function or activity of one or more cytoplasmic receptors.

### Claim 139 (depends on 4)

The method of claim 4 wherein the compound modulates the structure, function or activity of one or more nuclear receptors.

### Claim 140 (depends on 4)

The method of claim 4 wherein the compound modulates the structure, function or activity of one or more steroid receptors.

### Claim 141 (depends on 4)

The method of claim 4 wherein the compound modulates the structure, function or activity of one or more aryl-hydrocarbon receptors.

### Claim 142 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by disruption of the activity of exogenous toxins.

### Claim 143 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by disruption of the activity of bacterial toxins, antigens or components.

### Claim 144 (depends on 142)

The method of claim 142, wherein the compound modulates interactions by disruption of the effects of anthrax toxin.

### Claim 145 (depends on 142)

Them method of claim 142, wherein the compound modulates interactions by disruption of the effects of botulinum toxin.

### Claim 146 (depends on 142)

The method of claim 142, wherein the compound modulates interactions by disruption of the effects of staphylococcal enterotoxin B.

### Claim 147 (depends on 142)

The method of claim 142, wherein the compound modulates interactions by disruption of the effects of Panton-Valentine leukocidin.

### Claim 148 (depends on 142)

The method of claim 142, wherein the compound modulates interactions by disruption of the effects of Shiga toxins.

### Claim 149 (depends on 142)

The method of claim 142, wherein the compound modulates interactions by disruption of the effects of cholera toxin.

### Claim 150 (depends on 142)

The method of claim 142, wherein the compound modulates interactions by disruption of the effects of mycolactones.

### Claim 151 (depends on 142)

The method of claim 142, wherein the compound modulates interactions by disruption of the effects of edaxadienes.

### Claim 152 (depends on 142)

The method of claim 142, wherein the compound modulates interactions by disruption of the effects of bacterial lipopolysaccharides.

### Claim 153 (depends on 142)

The method of claim 142, wherein the compound modulates interactions by disruption of the effects of pneumolysin.

### Claim 154 (depends on 142)

The method of claim 142, wherein the compound modulates interactions by disruption of the effects of cholesterol dependent cytolysins.

### Claim 155 (depends on 142)

The method of claim 142, wherein the compound modulates interactions by disruption of hemolysins.

### Claim 156 (depends on 142)

The method of claim 142, wherein the compound modulates interactions by disruption of RTX toxins.

### Claim 157 (depends on 142)

The method of claim 142, wherein the compound modulates interactions by disruption of the effects of endotoxins.

### Claim 158 (depends on 142)

The method of claim 142, wherein the compound modulates interactions by disruption of the effects of cytolysin A.

### Claim 159 (depends on 142)

The method of claim 142, wherein the compound modulates interactions by disruption of the effects of Gramicidin A.

### Claim 160 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by disruption of the activity of viral toxins, antigens or components.

### Claim 161 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by disruption of the activity of fungal toxins, antigens or components.

### Claim 162 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by disruption of the activity of chemical toxins, antigens or components.

### Claim 163 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by disruption of the activity of environmental toxins, pollutants or antigens.

### Claim 164 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by disruption or alteration of viral capsid assembly, processing, endocytosis, exocytosis or budding.

### Claim 165 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by disruption or alteration of viral particle binding to cellular receptors or docking molecules.

### Claim 166 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by disruption or alteration of viral particle assembly.

### Claim 167 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by disruption or alteration of viral cholesterol homeostasis, utilization, processing or incorporation.

### Claim 168 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by disruption or alteration of viral particle cellular or nuclear membrane penetration.

### Claim 169 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by disruption or alteration of viral particle penetration of endocytic or pinocytic membranes.

### Claim 170 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by disruption or alteration of virus induced cellular signaling responses.

### Claim 171 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by disruption or alteration of prion interactions with its targets.

### Claim 172 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by disruption or alteration of microRNA interactions with its targets.

### Claim 173 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by disruption or alteration of single and double stranded DNA interactions with its targets.

### Claim 174 (depends on 4)

The method of claim 4, wherein the compound modulates interactions by disruption or alteration of single and double stranded RNA interactions with its targets.

### Claim 175

A method of treating medical or cosmetic conditions comprising administering topically, nasally, orally or parenterally, at least one azelaic acid ester compound in combination with at least one other pharmaceutical treatment to modulate interactions between at least 2 biological molecules in an organism.

### Claim 176

The method of treating medical or cosmetic conditions of wherein the at least one azelaic acid ester compound modulates interactions between at least 2 biological molecules in the organism, thereby enhancing the ability of the treatment to treat the organism.

### Claim 177 (depends on 175)

The method of claim 175, wherein the treatment is heparin.

### Claim 178 (depends on 175)

The method of claim 175, wherein the treatment is an antibiotic.

### Claim 179 (depends on 175)

The method of claim 175, wherein the treatment is an antiviral agent.

### Claim 180 (depends on 175)

The method of claim 175, wherein the treatment is an antifungal agent.

### Claim 181 (depends on 175)

The method of claim 175, wherein the treatment is an anti-inflammatory agent.

### Claim 182 (depends on 175)

The method of claim 175, wherein the treatment is an anti-cancer agent.

### Claim 183 (depends on 175)

The method of claim 175, wherein the treatment is an antibody.

### Claim 184 (depends on 175)

The method of claim 175, wherein the treatment is a receptor agonist.

### Claim 185 (depends on 175)

The method of claim 175, wherein the treatment is a receptor antagonist.

### Claim 186 (depends on 4)

The method of claim 4 wherein the modulation interaction comprises modifying, altering, abolishing, decreasing or increasing the activity of immune system cells.

### Claim 187 (depends on 186)

The method of claim 186, where the immune system cell is a macrophage.

### Claim 188 (depends on 186)

The method of claim 186, where the immune system cell is a neutrophil.

### Claim 189 (depends on 186)

The method of claim 186, where the immune system cell is a B cell.

### Claim 190 (depends on 186)

The method of claim 186, where the immune system cell is a T cell.

### Claim 191 (depends on 186)

The method of claim 186, where the immune system cell is an antigen-presenting cell.

### Claim 192 (depends on 186)

The method of claim 186, where the immune system cell is a plasma B cell.

### Claim 193 (depends on 186)

The method of claim 186, where the immune system cell is a monocyte.

### Claim 194 (depends on 186)

The method of claim 186, where the immune system cell is a stem cell.

### Claim 195 (depends on 186)

The method of claim 186, where the immune system cell is a bone marrow derived progenitor cell.

### Claim 196 (depends on 186)

The method of claim 186, where the immune system cell is a dendritic cell.

### Claim 197 (depends on 186)

The method of claim 186, where the immune system cell is a Langerhans cell.

### Claim 198 (depends on 186)

The method of claim 186, where the immune system cells is a T-helper cell.

### Claim 199 (depends on 186)

The method of claim 186, where the immune system cell is a natural killer T cell.

### Claim 200 (depends on 186)

The method of claim 186, where the immune system cell is a delta-gamma-T cell.

### Claim 201 (depends on 186)

The method of claim 186, where the immune system cell is a T-helper type 17 cell.

### Claim 202 (depends on 186)

The method of claim 186, where the immune system cell is a T-helper type 1 cell.

### Claim 203 (depends on 186)

The method of claim 186, where the immune system cell is a T-helper type 2 cell.

### Claim 204 (depends on 186)

The method of claim 186, where the immune system cell is a T-helper type 3 cell.

### Claim 205 (depends on 186)

The method of claim 186, where the immune system cell is a T-follicular helper type cell.

### Claim 206 (depends on 186)

The method of claim 186, where the immune system cell is a T-regulatory type cell.

### Claim 207 (depends on 186)

The method of claim 186, where the immune system cell is a cytotoxic T cell.

### Claim 208 (depends on 186)

The method of claim 186, where the immune system cell is a naïve type T cell.

### Claim 209 (depends on 186)

The method of claim 186, where the immune system cell is a follicular dendritic cell.

### Claim 210 (depends on 186)

The method of claim 186, where the immune system cell is a plasmacytoid dendritic cell.

### Claim 211 (depends on 186)

The method of claim 186, where the immune system cell is an inflammatory dendritic cell.

### Claim 212 (depends on 4)

The method of claim 4 wherein the modulation interaction comprises the modulation of the structure, function or activity of DNA-PK complexes.

### Claim 213 (depends on 4)

The method of claim 4 wherein the modulation interaction comprises the modulation of the structure, function or activity of the Human Antimicrobial Peptide LL37.

### Claim 214 (depends on 4)

The method of claim 4 wherein the modulation interaction comprises the modulation of the structure, function or activity of Glycipan-1.
